ReviewThe oncologist2026
Skin health in oncology: evidence-based skin care for cancer patients.
Review in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.Experimental hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer and its treatments frequently compromise skin integrity, leading to xerosis, pruritus, dermatitis, radiation-induced skin damage, and secondary infections. These cutaneous adverse events (cAEs) are not merely superficial; they profoundly impact patient quality of life (QoL), contributing to physical discomfort, psychosocial distress, and poorer treatment adherence. Even mild skin toxicities elevate dermatology-specific QoL measures, affecting mood and social function. Additionally, new targeted therapies, such as daraxonrasib-a KRAS inhibitor under development for pancreatic cancer-can cause a dose-limiting acneiform facial rash.
methodsIn this study, relevant literature on skin care in cancer patients was identified using PubMed. Evidence from clinical studies, reviews, and expert guidelines was summarized.
resultsEvidence supports proactive skincare with gentle pH-balanced cleansers, ceramide- or urea-based moisturizers, and broad-spectrum photoprotection to lessen symptom severity and improve QoL. Sun protection remains essential because chemotherapy and immunomodulatory therapies increase photosensitivity, accelerate photoaging, and raise the risk of secondary skin cancers. Supportive skincare interventions have also shown emotional and functional benefits, including improved mood and self-image during chemotherapy and radiation treatment.
conclusionDespite strong data supporting moisturization, barrier repair, and photoprotection, oncologic treatment plans often overlook these interventions. By integrating dermatologic education and skincare maintenance into standard oncologic practice, we can minimize cAEs, foster treatment compliance, and enhance patients' physical comfort and psychosocial well-being. This narrative review synthesizes mechanistic insights, clinical evidence, and practical recommendations for oncologists to champion comprehensive skincare in all cancer patients, whether directly affected by skin issues or not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.